Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Collegium Pharmaceutical Inc (NASDAQ:COLL) decreased during the last reporting period, falling from 6.29M to 6.11M. This put 23.48% of the company's publicly available shares short.

STOUGHTON, Mass. - Collegium Pharmaceutical , Inc. (NASDAQ:COLL) announced today its decision to redeem all outstanding 2.625% Convertible Senior Notes due in 2026. The total ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.